Influence of obesity on atherogenic dyslipidemia in women with polycystic ovary syndrome

European Journal of Clinical Investigation

Volumn 43, Issue 6, 2013, Pages 549-556

  Hernández Mijares, Antonio ^a,b,c,d   Bañuls, Celia ^a,c,d   Gómez Balaguer, Marcelino ^a   Bergoglio, Marina ^a   Víctor, Victor M ^a,b,c,d   Rocha, Milagros ^a,b,c,d  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d Instituto Universitario IVI INCLIVA   (Spain)

Author keywords

Atherogenic dyslipidemia; HDL subfractions; LDL subfractions; Obesity; Polycystic ovary syndrome

Indexed keywords

ANDROSTENEDIONE; APOLIPOPROTEIN A1; ESTRADIOL; FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYPROGESTERONE; INSULIN; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ANDROGEN BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; ATHEROGENIC DYSLIPIDEMIA; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; ESTRADIOL BLOOD LEVEL; FEMALE; GESTAGEN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; ATHEROSCLEROSIS; BODY MASS INDEX; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; HUMANS; OBESITY; POLYCYSTIC OVARY SYNDROME; RISK FACTORS;

EID: 84877714705     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12080     Document Type: Article

References (27)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-11.
2. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-36.
3. Sukalich S, Guzick D. Cardiovascular health in women with polycystic ovary syndrome. Semin Reprod Med 2003;21:309-15.
4. Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 2011;17:741-60.
5. Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006;185:227-39.
6. Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids 2010;45:907-14.
7. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006;3:144-53.
8. Dejager S, Pichard C, Giral P, Bruckert E, Federspield MC, Beucler I et al. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol (Oxf) 2001;54:455-62.
9. Berneis K, Rizzo M, Lazzarini V, Fruzzetti F, Carmina E. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:186.
10. Doi SA, Abbas JM, Parkinson L, Chakraborty J, Akanji AO. LDL species heterogeneity in the atherogenic dyslipidemia of polycystic ovary syndrome. Am J Clin Pathol 2008;129:802-10.
11. Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB et al. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod 2009;24:2286-92.
12. Legro RS, Blanche P, Krauss RM, Lobo RA. Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. Fertil Steril 1999;72:990-5.
13. Sidhwani S, Scoccia B, Sunghay S, Stephens-Archer CN, Mazzone T, Sam S. PCOS is associated with atherogenic changes in lipoprotein particle number and size independent of body weight. Clin Endocrinol (Oxf) 2011, in press, doi: 10.1111/j.1365-2265.2011.04015.x.
14. Phelan N, O'Connor A, Kyaw-Tun T, Correia N, Boran G, Roche HM et al. Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) compared with equally insulin-resistant women without PCOS. J Clin Endocrinol Metab 2010;95:3933-9.
15. Cupisti S, Giltay EJ, Gooren LJ, Kronawitter D, Oppelt PG, Beckmann MW et al. The impact of testosterone administration to female-to-male transsexuals on insulin resistance and lipid parameters compared with women with polycystic ovary syndrome. Fertil Steril 2010;94:2647-53.
16. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
17. Hoefner DM, Hodel SD, O'Brien JF, Branum EL, Sun D, Meissner I et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem 2001;47:266-74.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:48-97.
19. Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 2008;93:470-6.
20. Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011;95:1073-9.e1-11.
21. Castelo-Branco C, Steinvarcel F, Osorio A, Ros C, Balasch J. Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism. Gynecol Endocrinol 2010;26:736-42.
22. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003;31:1066-9.
23. Koba S, Yokota Y, Hirano T, Ito Y, Ban Y, Tsunoda F et al. Small LDL-cholesterol is superior to LDL-cholesterol for determining severe coronary atherosclerosis. J Atheroscler Thromb 2008;15:250-60.
24. Moon JY, Kwon HM, Kwon SW, Yoon SJ, Kim JS, Lee SJ et al. Lipoprotein(a) and LDL particle size are related to the severity of coronary artery disease. Cardiology 2007;108:282-9.
25. Packard CJ. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol 2006;17:412-7.
26. Fruzzetti F, Perini D, Lazzarini V, Parrini D, Genazzani AR. Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels. Fertil Steril 2009;92:626-34.
27. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 2007;18:280-5.